Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15077830 | 0.89 | IGF1R (0.46) | IGF1RCYP17A1CCR2GSK3BDYRK1A | |
| SCHEMBL15354529 | 0.89 | RIOK2 (0.50) | IGF1RCYP17A1CCR2GSK3BDYRK1A | |
| SCHEMBL15077836 | 0.88 | IGF1R (0.46) | IGF1RCYP17A1CCR2GSK3BDYRK1A | |
| SCHEMBL12695309 | 0.86 | NR3C2 (0.47) | IGF1RCYP17A1CCR2NR3C2ATR | |
| SCHEMBL29575346 | 0.86 | IGF1R (0.48) | IGF1RCYP17A1CCR2GSK3BDYRK1A | |
| SCHEMBL1940483 | 0.86 | IGF1R (0.48) | IGF1RCYP17A1CCR2GSK3BDYRK1A | |
| SCHEMBL12953977 | 0.85 | IGF1R (0.47) | IGF1RCYP17A1CCR2GSK3BDYRK1A | |
| SCHEMBL626850 | 0.85 | LOXL2 (0.51) | IGF1RCYP17A1CCR2NR3C2ATR | |
| SCHEMBL10087555 | 0.85 | NR3C2 (0.49) | IGF1RCYP17A1CCR2GSK3BDYRK1A | |
| SCHEMBL167992 | 0.85 | IGF1R (0.47) | IGF1RCYP17A1CCR2GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | IGF1R 1639/4885CYP17A1 3924/4885CCR2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.